[Guillain-Barré syndrome associated with Epstein-Barr virus and cytomegalovirus reactivation during treatment for chronic graft-versus-host disease after allogeneic bone marrow transplantation]

Hiroki Hosoi,Misato Tane,Hideki Kosako,Ayaka Sakaki,Yoshimitsu Wada,Yoshiaki Nakayama,Takayuki Hiroi,Yoshikazu Hori,Yusuke Yamashita,Toshiki Mushino,Shogo Murata,Akinori Nishikawa,Katsuichi Miyamoto,Hidefumi Ito,Takashi Sonoki
DOI: https://doi.org/10.11406/rinketsu.64.1280
Abstract:Guillain-Barré syndrome (GBS) is a rare neurological complication of allogeneic hematopoietic stem cell transplantation (HSCT). The pathogenesis of post-HSCT GBS is unclear. Here, we report a case of GBS coincident with Epstein-Barr virus (EBV) and cytomegalovirus (CMV) reactivation that occurred after HSCT in a patient with myelodysplastic syndrome. A 61-year-old man was admitted to our hospital because of gait disturbance due to lower limb muscle weakness, which arose during treatment for chronic graft-versus-host disease (GVHD) five months after allogeneic HSCT. He was diagnosed with GBS based on his clinical course, cerebrospinal fluid analysis, and a nerve conduction study. At that time, he exhibited EBV and CMV reactivation. GBS improved after intravenous injection of immunoglobulins. Our case suggests that reactivation of EBV and CMV during treatment for chronic GVHD may induce GBS, and that rapidly progressive muscular weakness coincident with EBV or CMV reactivation can be a diagnostic sign of GBS after allogeneic HSCT.
What problem does this paper attempt to address?